Anti Human VLDL receptor Antibody Monoclonal,VR-VP1-5C3

Anti Human VLDL receptor Antibody Monoclonal,VR-VP1-5C3
 

DiagnoCine offers excellent VLDL (Very Low-Density Lipoprotein) Receptor | VLDLR Antibody  to researchers studying  receptor-mediated endocytosis of specific ligands, VLDL-triglyceride metabolism, reelin signaling pathway, VLDLR-associated cerebellar hypoplasia, and calcium ion binding

Human diseases include Cerebellar Ataxia, Mental Retardation, Dysequilibrium Syndrome 1, Cerebellar Hypoplasia, and multiple mental disorders.
 
VLDL (Very Low-Density Lipoprotein) Receptor | VLDLR Antibody   has excellent quality and this highly pure antibody can be adapted for Western Blots, IHC, and other methods with optimization.   

General information 

Cat. No.	：FNK-BML030
Size	：50µg
Clone	：VR-VP1-5C3
Antigen	：Human
Host Animal	：Mouse
Cross Reactivity	：Human
Labeled	：Unlabeled
Preparation	：Produced in mice immunized with synthetic peptides, amino acid residue 1-18 (GRKAKCEPSQFQCTNGRC),     which is corresponding to the NH3-terminus of human very low-density lipoprotein (VLDL) receptor (VLDL-R).     VLDL-R specific IgG was purified from mouse ascites fluid with a proteinA-Sepharose.
Formulation	：0.2 µm filtered PBSsolution
Specificity	：This antibody has been selected for its ability to bind for human VLDL-R expressed in CHO cells (ldl-A7).     No cross-reactivity with human LDL receptor and apoER2 receptor was confirmed (see ref. 1)
Application	：Western blot - This antibody can be used at 1.0 µg/mL for western blot analysis (1). ：Flowcytometry - This antibody can be used as a 1st antibody for immunohistochemistry.                               Please see the references (2) and (3) for details. ：Immunohistochemistry - This antibody can be used for immunohistochemistry (4). ：Optimal dilutions should be determined by each laboratory for each application.
Immunogen	：synthetic peptide
Ig Isotype	：IgG2b
Storage	：IgG in PBS solution are stable for twelve months from the date of receipt when stored at-80˚C.     Avoid repeated freeze-thaw cycles.

 

Antigen Characterization   

Type	：Lipoprotein
Application	：Lipid metabolism studies, Cardiovascular research, Atherosclerosis research
Species	：Human
Recombinant	：Yes

VLDL in the Cell

• Interaction with cell surfaces: At the capillaries of target tissues (like adipose tissue and muscle), VLDL interacts with lipoprotein lipase (LPL) on the surface of endothelial cells.
• Lipid delivery: LPL, activated by apoC-II on the VLDL surface, breaks down triglycerides in VLDL, releasing free fatty acids. These fatty acids can then be taken up by nearby cells for energy use or storage.
• VLDL remnant formation: As VLDL loses triglycerides, it becomes denser and transforms into intermediate-density lipoprotein (IDL) and eventually low-density lipoprotein (LDL) LDL uptake: Cells with LDL receptors, including liver cells and various other tissue cells, can take up LDL particles through receptor-mediated endocytosis.

VLDL in the Human Body

VLDL is often referred to as "bad" cholesterol, similar to LDL, because high levels of VLDL can contribute to the buildup of plaque in the arteries, a condition known as atherosclerosis. This plaque buildup can narrow the arteries and restrict blood flow, increasing the risk of heart disease and stroke.

High levels of VLDL are associated with several health issues, including:

• Atherosclerosis: Plaque buildup in the arteries leading to cardiovascular diseases.
• Metabolic Syndrome: A cluster of conditions that increase the risk of heart disease, stroke, and diabetes.
• Insulin Resistance: Reduced ability of cells to respond to insulin, often seen in type 2 diabetes.
• Non-Alcoholic Fatty Liver Disease: Fat accumulation in the liver not due to alcohol consumption.

References

1. Kosaka et al., Evidence of macrophage form cell formation by very low-density lipoprotein receptor: Interferon-γ inhibition of very low-density lipoprotein receptor expression and form cell formation in macrophages. Circulation,2001;103:1142-1147.
2. Iwasaki et al., The important role for ßVLDLs binding at the forth cysteine of first ligand-binding domain in the low-density lipoprotein receptor. J Hum Genet,2004;49:622-628.
3. Iwasaki etal., Deficiency ofthe very low-density lipoprotein (VLDL) receptors in streptozotocin-induced diabetic rats: insulin dependency of the VLDL receptor.Endocrinology, 2005;146:3286-3294.
4. Motoi et al., Apolipoprotein E receptor 2 is involved in neurotic plaque formation inAPPsw mice.Neurosci Lett,2004;368:144-147.